Opioid Induced Constipation Drugs Market

Opioid Induced Constipation Drugs Market Size Survey Report – In a Glance

As per the survey report on global Opioid Induced Constipation Drugs market, the market is projected to foresee a CAGR of CAGR value 6.7% between 2024-2033, and further generate a market size of USD 4.8 Billion revenue billion by the end of 2033. In the year 2024, the market size was valued at USD 2.7 Billion revenue billion.

• The global Opioid Induced Constipation Drugs market is projected to grow on account of the increased prevalence of opioid use.
• In Japan, the Opioid Induced Constipation Drugs market growth can be attributed to the increased aged population.
• KDMI analyst’s growth analysis foresees Safety Concerns Impacting OIC Drugs to challenge the market growth.
• North America, having the highest market share in the Opioid Induced Constipation Drugs market, is projected to dominate the global market.

Opioid Induced Constipation Drugs Market Analysis

Opioid-induced constipation (OIC) is a medical condition in which a person suffers from gastrointestinal issues like reduced intestinal motility, reduced fluid secretion, and severe constipation due to the excessive use of opioid medications which is a very effective pain-killer. The upward trend in opioid prescription for pain relief has led to a heightened incidence of opioid-induced constipation (OIC) across the globe, promoting the Opioid Induced Constipation Drugs market. On a global scale, the prevalence of OIC ranges from 8.9% to 81.0% due to the extended use of opioid medications and it was found that OIC was much more common in children diagnosed with acute lymphoblastic leukemia with a prevalence of 33.9%.

Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel) are some of the significant parties in the global market for Opioid Induced Constipation Drugs.

Analyst’s Observation on Japan Opioid Induced Constipation Drugs Market Survey

In Japan, the market growth for Opioid Induced Constipation Drugs can be attributed to the increased aged population. Constipation is more frequently encountered among the senior citizens of the country, shifting Japan’s demographic of opioid-induced constipation drugs market towards the older age group. According to a survey in 2022, Japan has the largest global rate of a population aged 65 or older with 29.1%. It has been reported that individuals suffering from constipation are more associated with increased mortality and cardiovascular incidents, with a 12% higher chance of all-cause mortality, 11% higher incidence of coronary heart disease, and 19% higher incidence of ischemic stroke. Daiichi Sankyo Co Ltd., Pfizer, Progenics Pharmaceuticals Inc are some of the significant parties in the market for Opioid Induced Constipation Drugs in Japan.

Opioid Induced Constipation Drugs Market Growth Driver

Accelerated Drug Approval Initiatives:

To streamline the approval process for the latest opioid-induced constipation (OIC) drugs, regulatory agencies have enforced programs that attempt to address the immediate need for result-oriented treatments by minimizing the time and resources required for drug development and authorization. Expediting the regulatory process less complicated helps pharmaceutical companies bring OIC drugs to the market sooner, delivering patients quicker access to innovative treatments, and eventually aiding the growth of the OIC drugs market. According to recent data, the Center for Drug Evaluation and Research (CDER) sanctioned 55 new drugs that were approved and marketed for the first time in the U.S. in 2023 and were known as ‘novel drugs’.

Opioid Induced Constipation Drugs Market Segmentation

Our experts at KD Market Insights have segmented the global Opioid Induced Constipation Drugs market research report as:

Opioid Induced Constipation Drugs Market Regional Synopsis

North America, Having The Highest Market Share Opioid Induced Constipation Drugs market is majorly driven by the existence of major product manufacturers, which promotes a thriving market of Opioid Induced Constipation (OIC) Drugs. Furthermore, a substantial increase in research and development strategies is also targeting developing innovative treatments for OIC, further advancing market development. According to National Center for Drug Abuse Statistics reports, out of the total individuals in America with drug disorders, 24.7% have an opioid disorder which includes prescription pain relievers or “pain killers” and heroin.

As per our analysts at KD Market Insights, the following five players lead the North America Opioid Induced Constipation Drugs market growth:

• Pfizer
• Mylan N.V.
• Hikma Pharmaceutical PLC
• Abbott
• Merck & Co. Inc.

Opioid Induced Constipation Drugs Market Competitive Landscape

Some of the key players who top the global Opioid Induced Constipation Drugs market share:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K.)
• Bayer AG (Germany)

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Opioid Constipation Drugs Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Active ingredients
      2. By Treatment
      3. By Route of administration
      4. By End-users
      5. By Distribution Channels
      6.  By Region
5. Market Segmentation by Active ingredients
   1. 1. Naloxegol
      2. Lubiprostone
      3. Methylnaltrexone Bromide
      4. Docusate Sodium
      5. Others
6. Market Segmentation by Treatment
   1. 1. Over The Counter Medicines
      2. Prescription
      3. Natural Remedies
7. Market Segmentation by Route of administration
   1. 1. Oral
      2. Parenteral
      3. Others
8. Market Segmentation by End-users
   1. 1. Hospitals
      2. Homecare
      3. Speciality Centres
      4. Others
9. Market Segmentation by Distribution channels
   1. 1. Hospital Pharmacy
      2. Online Pharmacy
      3. Retail Pharmacy
10. Regional Analysis
    1. North America
       1. United States
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
       2. Canada
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       3. Mexico
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
    2. Europe
       1. United Kingdom
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
       2. Germany
          1. Market Size and Forecast
          2. Key Trends and Developments
       3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
       4. France
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
       5. Italy
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
       6. Spain
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
       7. Rest of Europe
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
    3. Asia Pacific
       1. China
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       2. Japan
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       3. India
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
       4. Australia
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4. South Korea
          5. Market Size and Forecast
          6. Key Trends and Developments
          7. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          8.  
       5. Rest of Asia Pacific
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
    4. Latin America
       1. Brazil
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       2. Argentina
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       3. Colombia
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       4. Rest of Latin America
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
    5. Middle East & Africa
       1. South Africa
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       2. Saudi Arabia
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       3. UAE
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
          4.  
       4. Rest of Middle East & Africa
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Active ingredients, Treatment, Route of administration, End-users, Distribution channels
11. Competitive Landscape
    1. Market Share Analysis
    2. Company Profiles
    3. Medtronic (Ireland)
    4. IBM
    5. Apple Inc.
    6. Siemens Medical Solutions
    7. Pepperl+Fuchs
    8. Cisco
    9. GE Healthcare
12. Strategic Recommendations
13. Appendix
    1. List of Tables
    2. List of Figures
14. References